2024
A Multicenter Evaluation of the Impact of Therapies on Deep Learning-based Electrocardiographic Hypertrophic Cardiomyopathy Markers
Dhingra L, Sangha V, Aminorroaya A, Bryde R, Gaballa A, Ali A, Mehra N, Krumholz H, Sen S, Kramer C, Martinez M, Desai M, Oikonomou E, Khera R. A Multicenter Evaluation of the Impact of Therapies on Deep Learning-based Electrocardiographic Hypertrophic Cardiomyopathy Markers. The American Journal Of Cardiology 2024 PMID: 39581517, DOI: 10.1016/j.amjcard.2024.11.028.Peer-Reviewed Original ResearchCleveland Clinic FoundationHypertrophic cardiomyopathyMedian follow-up periodHypertrophic cardiomyopathy therapyMonitoring treatment responseFollow-up periodImpact of therapyAtlantic Health SystemLack of improvementOral alternativePost-SRTMedical therapyTreatment responseMulticenter evaluationInterventricular septumPercutaneous reductionMavacamtenTherapyPatientsClinic FoundationPoint-of-care monitoringECGECG imagesScoresHealth system
2022
Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data
Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. Frontiers In Cardiovascular Medicine 2022, 9: 829553. PMID: 35369354, PMCID: PMC8964995, DOI: 10.3389/fcvm.2022.829553.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMagnetic resonance imagingExtracellular volumeEarly detectionImmune checkpoint inhibitionWall motion abnormalitiesCancer therapyMechanisms of cardiotoxicityTyrosine kinase inhibitorsCurrent imaging modalitiesAssessment of functionCardioprotective medicationsCardiotoxic eventsMolecular radiotracersCardiovascular outcomesMolecular imagingCheckpoint inhibitionNovel cancer therapiesOncologic therapyCancer mortalityMyocardial infarctionMotion abnormalitiesCardiac metabolismCardiotoxicityResonance imagingTherapy
2019
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience
Chuy K, Oikonomou EK, Postow MA, Callahan MK, Chapman PB, Shoushtari AN, Neilan TG, Fradley MG, Ramanathan LV, Wolchok JD, Steingart RM, Gupta D. Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. The Oncologist 2019, 24: e196-e197. PMID: 30910868, PMCID: PMC6516118, DOI: 10.1634/theoncologist.2019-0040.Peer-Reviewed Original ResearchConceptsCombination immune checkpoint inhibitor therapyImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyInhibitor therapyMemorial Sloan-Kettering Cancer Center experienceCancer Center experienceSafety Working GroupAdvanced melanomaCenter experienceConsensus documentPatientsTherapyWorking GroupMyocarditisMelanoma